Who
Alexander M. Gold
Director
Company insider
Files Form 4 as: Director, Mineralys Therapeutics.
In numbers
- Trades disclosed
- 19
- Buys
- 0
- Sells
- 3
- Bought
- $0
- Sold
- $1.6M
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 13 Jun 2024
- Last trade
- 19 Feb 2026
- Last filed
- 20 Feb 2026
Companies traded
Activity over time
1 Nov 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 19 Feb 2026filed 20 Feb 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Code A | —6,200 at $0.00 | filing |
| 19 Feb 2026filed 20 Feb 2026 | MLYS Mineralys Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,300 at $0.00 | filing |
| 19 Feb 2026filed 20 Feb 2026 | MLYS Mineralys Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,300 at $0.00 | filing |
| 19 Feb 2026filed 20 Feb 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Code A | —6,200 at $0.00 | filing |
| 13 Nov 2025filed 13 Nov 2025 | MLYS Mineralys Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,742 at $0.00 | filing |
| 13 Nov 2025filed 13 Nov 2025 | MLYS Mineralys Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 13 Nov 2025filed 13 Nov 2025 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Code M | $28K2,742 at $10.20 | filing |
| 13 Nov 2025filed 13 Nov 2025 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Code M | $127K10,000 at $12.69 | filing |
| 13 Nov 2025filed 13 Nov 2025 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Sold | $593K12,742 at $46.50 | filing |
| 12 Nov 2025filed 13 Nov 2025 | MLYS Mineralys Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,933 at $0.00 | filing |
| 12 Nov 2025filed 13 Nov 2025 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Code M | $71K6,933 at $10.20 | filing |
| 12 Nov 2025filed 13 Nov 2025 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Sold | $233K5,000 at $46.50 | filing |
| 12 Nov 2025filed 13 Nov 2025 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Sold | $91K1,933 at $47.28 | filing |
| 11 Nov 2025filed 13 Nov 2025 | MLYS Mineralys Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —15,000 at $0.00 | filing |
| 11 Nov 2025filed 13 Nov 2025 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Code M | $153K15,000 at $10.20 | filing |
| 11 Nov 2025filed 13 Nov 2025 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Sold | $424K10,000 at $42.43 | filing |
| 11 Nov 2025filed 13 Nov 2025 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Sold | $235K5,000 at $47.08 | filing |
| 13 Feb 2025filed 24 Feb 2025 | MLYS Mineralys Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,900 at $0.00 | filing |
| 13 Jun 2024filed 17 Jun 2024 | MLYS Mineralys Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,000 at $0.00 | filing |
News
Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel CoatsMLYS · manilatimes.net · 19 Oct 2026
0 headlines in the last 90 days name Alexander M. Gold; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.